(Q44482611)

3 December 2017

title

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis (English)

1 reference

3 December 2017

0 references

James D Bowen

1

1 reference

3 December 2017

Kenneth Maravilla

series ordinal

2

1 reference

3 December 2017

Solomon B Margolin

series ordinal

3

1 reference

3 December 2017

publication date

1 June 2003

1 reference

Multiple Sclerosis Journal

3 December 2017

published in

1 reference

3 December 2017

volume

9

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

280-283

1 reference

Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Pirfenidone in the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS907OA

10.1191/1352458503MS907OA

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference